- Home
- STK vs ZVRA Comparison
STK vs ZVRA Comparison
Compare STK & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- ZVRA
- Stock Information
- Founded
- STK 2009
- ZVRA 2006
- Country
- STK United States
- ZVRA United States
- Employees
- STK N/A
- ZVRA N/A
- Industry
- STK Investment Managers
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- STK Finance
- ZVRA Health Care
- Exchange
- STK Nasdaq
- ZVRA Nasdaq
- Market Cap
- STK 553.2M
- ZVRA 473.6M
- IPO Year
- STK N/A
- ZVRA 2015
- Fundamental
- Price
- STK $33.39
- ZVRA $9.09
- Analyst Decision
- STK
- ZVRA Strong Buy
- Analyst Count
- STK 0
- ZVRA 7
- Target Price
- STK N/A
- ZVRA $21.20
- AVG Volume (30 Days)
- STK 38.2K
- ZVRA 669.7K
- Earning Date
- STK 01-01-0001
- ZVRA 11-12-2024
- Dividend Yield
- STK 6.60%
- ZVRA N/A
- EPS Growth
- STK N/A
- ZVRA N/A
- EPS
- STK N/A
- ZVRA N/A
- Revenue
- STK N/A
- ZVRA $24,489,000.00
- Revenue This Year
- STK N/A
- ZVRA N/A
- Revenue Next Year
- STK N/A
- ZVRA $318.48
- P/E Ratio
- STK N/A
- ZVRA N/A
- Revenue Growth
- STK N/A
- ZVRA 47.85
- 52 Week Low
- STK $24.95
- ZVRA $4.20
- 52 Week High
- STK $34.31
- ZVRA $9.27
- Technical
- Relative Strength Index (RSI)
- STK 51.38
- ZVRA 59.84
- Support Level
- STK $32.86
- ZVRA $8.32
- Resistance Level
- STK $33.46
- ZVRA $9.27
- Average True Range (ATR)
- STK 0.46
- ZVRA 0.53
- MACD
- STK -0.02
- ZVRA 0.00
- Stochastic Oscillator
- STK 60.57
- ZVRA 81.82
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.